Alexandria Venture Investments, LLC - Oct 26, 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
By: ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member By: /s/ Dean A. Shigenaga Chief Financial Officer
Stock symbol
XLO
Transactions as of
Oct 26, 2021
Transactions value $
$0
Form type
4
Date filed
10/26/2021, 04:51 PM
Previous filing
Oct 21, 2021
Next filing
Jan 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction XLO Common stock Conversion of derivative security +166K 166K Oct 26, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Series B convertible preferred stock Conversion of derivative security -1.58M -100% 0 Oct 26, 2021 Common stock 166K Direct F1, F2

Alexandria Venture Investments, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.
F2 Not applicable.